Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Filings indexed 329 across all filing types
Latest filing 2026-04-09 Annual Report
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
ARS - ProMIS Neurosciences Inc. (0001374339) (Filer)
Annual Report
2026-04-09 English
DEF 14A - ProMIS Neurosciences Inc. (0001374339) (Filer)
Proxy Solicitation & Information Statement
2026-04-09 English
EFFECT - ProMIS Neurosciences Inc. (0001374339) (Filer)
Regulatory Filings
2026-03-27 English
S-3 - ProMIS Neurosciences Inc. (0001374339) (Filer)
Registration Form
2026-03-25 English
8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
Regulatory Filings
2026-03-25 English
SCHEDULE 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)
Major Shareholding Notification
2026-03-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.